- Home
- CPB vs BBIO Comparison
CPB vs BBIO Comparison
Compare CPB & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPB
- BBIO
- Stock Information
- Founded
- CPB 1869
- BBIO 2015
- Country
- CPB United States
- BBIO United States
- Employees
- CPB N/A
- BBIO N/A
- Industry
- CPB Packaged Foods
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CPB Consumer Staples
- BBIO Health Care
- Exchange
- CPB Nasdaq
- BBIO Nasdaq
- Market Cap
- CPB 9.2B
- BBIO 8.8B
- IPO Year
- CPB N/A
- BBIO 2019
- Fundamental
- Price
- CPB $32.51
- BBIO $51.32
- Analyst Decision
- CPB Hold
- BBIO Strong Buy
- Analyst Count
- CPB 17
- BBIO 16
- Target Price
- CPB $38.88
- BBIO $61.69
- AVG Volume (30 Days)
- CPB 5.0M
- BBIO 2.9M
- Earning Date
- CPB 08-28-2025
- BBIO 08-05-2025
- Dividend Yield
- CPB 4.80%
- BBIO N/A
- EPS Growth
- CPB N/A
- BBIO N/A
- EPS
- CPB 1.50
- BBIO N/A
- Revenue
- CPB $10,225,000,000.00
- BBIO $235,812,000.00
- Revenue This Year
- CPB $7.70
- BBIO $106.33
- Revenue Next Year
- CPB N/A
- BBIO $54.30
- P/E Ratio
- CPB $21.64
- BBIO N/A
- Revenue Growth
- CPB 8.65
- BBIO 7.62
- 52 Week Low
- CPB $29.39
- BBIO $21.72
- 52 Week High
- CPB $52.81
- BBIO $51.86
- Technical
- Relative Strength Index (RSI)
- CPB 52.88
- BBIO 68.33
- Support Level
- CPB $31.77
- BBIO $42.09
- Resistance Level
- CPB $32.81
- BBIO $51.86
- Average True Range (ATR)
- CPB 0.79
- BBIO 1.90
- MACD
- CPB 0.02
- BBIO 0.30
- Stochastic Oscillator
- CPB 62.71
- BBIO 94.47
About CPB Campbell Soup Company
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2024 (July year-end), snacks accounted for nearly half of its revenue, followed by soup (28%), other simple meals (17%), and beverages (7%). Outside its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and recently acquired Rao's (a deal that closed in March 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.